HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach
Update: 2025-12-10
Description
Featuring an interview with Dr John V Heymach, including the following topics:
- Differentiating factors among various HER2 alterations in non-small cell lung cancer (NSCLC) (0:00 )
- Activity of targeted agents across HER2 alterations in NSCLC (4:06 )
- Available data with zongertinib and sevabertinib for HER2-mutant NSCLC (20:39 )
- Case: A man in his late 40s with HER2-mutant NSCLC receives multiple lines of therapy, including trastuzumab deruxtecan (T-DXd) and zongertinib (29:23 )
- Case: A woman in her mid 50s with HER2-mutant NSCLC receives zongertinib with durable response (34:23 )
- Case: A woman in her late 50s with HER2-mutant NSCLC receives multiple lines of therapy, including sevabertinib and T-DXd (39:53 )
- Investigational approaches in HER2-mutant NSCLC (46:31 )
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
